Who we are
Neurovation Labs is a preclinical stage biotechnology company advancing
a precision approach to mental health disorders.
With our deep understanding of receptor biology, neuroscience, and translational medicine, we have developed a novel drug discovery platform, which we are using to create precision medicines for central nervous system (CNS) disorders. Most CNS drugs lack specificity, binding to receptor targets throughout the brain. The result: off-target binding and side effects.
We are currently focused on the discovery and development of a portfolio of region-selective small molecule candidates for ionotropic glutamate receptor-mediated disorders. Our lead asset is a small molecule Negative Allosteric Modulator (NAM) of amygdala-specific AMPA receptors for the treatment of PTSD.
Our game-changing approach has the potential to transform mental healthcare and treat CNS disorders at the source- the most logical target. We are committed to developing and commercializing effective, targeted therapies to end the mental health crisis.